KEYconversations in early-stage TNBC: Optimising treatment outcomes in early-stage triple-negative breast cancer January 2023 Highlights Report

Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland) [External links]

PDF,  2.41 MB

The MSD KEYTRUDA® (pembrolizumab) Launch Meeting in early-stage triple-negative breast cancer took place on the 27th of January 2023 at the Hilton London Tower Bridge. The event was chaired by Professor Peter Schmid, MD PhD FRCP (Consultant Medical Oncologist, Barts Cancer Institute, London).

Throughout multiple presentations, panel discussions, workshops and Q&A sessions panelists entered into a discussion about the evolving treatment landscape for early-stage triple-negative breast cancer (TNBC). The panelists also explored the data, rationale and patient eligibility for immuno-oncology (IO) as neo-adjuvant and adjuvant treatment in early-stage TNBC, and further examined adverse event management for patients being treated with IO for early-stage TNBC. Attendees were able to participate in the discussion through interactive workshops and via a digital polling system.

Read more about the day and the sessions in the above report.

Click on the resource to download.

KEYTRUDA, in combination with chemotherapy as neoadjuvant treatment, and then continued as monotherapy as adjuvant treatment after surgery, is indicated for the treatment of adults with locally advanced, or early-stage triple-negative breast cancer, at high-risk of recurrence.¹

Please refer to Summary of Product Characteristics for full list of AEs and management.

More information about KEYTRUDA® (pembrolizumab) in triple-negative breast cancer (TNBC)

Reference

1. KEYTRUDA Summary of Product Characteristics.

Supporting documentation

Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland)
By clicking the links above you will leave the MSD Connect website and be taken to the emc PI portal website